Arsenous acid
Star0
Identification
- Generic Name
- Arsenous acid
- DrugBank Accession Number
- DB04456
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
- Weight
- Average: 125.9436
Monoisotopic: 125.929815379 - Chemical Formula
- AsH3O3
- Synonyms
- arsenic trihydroxide
- arsenous acid
- arsorous acid
- trihydroxyarsenite(III)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UArsenate reductase Not Available Escherichia coli UArsenical pump-driving ATPase Not Available Escherichia coli - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as miscellaneous arsenites. These are inorganic compounds in which the largest metallic oxoanion is arsenite, to which either no atom or a non metal atom is bonded.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Miscellaneous mixed metal/non-metals
- Sub Class
- Miscellaneous metallic oxoanionic compounds
- Direct Parent
- Miscellaneous arsenites
- Alternative Parents
- Trivalent inorganic arsenic compounds / Metalloid salts / Inorganic salts
- Substituents
- Arsenite / Inorganic arsenic compound / Inorganic metalloid salt / Inorganic salt / Trivalent inorganic arsenic compound
- Molecular Framework
- Not Available
- External Descriptors
- arsenic oxoacid (CHEBI:49900)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 935XD1L5K2
- CAS number
- 13464-58-9
- InChI Key
- GCPXMJHSNVMWNM-UHFFFAOYSA-N
- InChI
- InChI=1S/AsH3O3/c2-1(3)4/h2-4H
- IUPAC Name
- arsorous acid
- SMILES
- O[As](O)O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0011620
- KEGG Compound
- C06697
- PubChem Compound
- 545
- PubChem Substance
- 46508436
- ChemSpider
- 530
- ChEBI
- 49900
- ChEMBL
- CHEMBL1236189
- PDBe Ligand
- TAS
- Wikipedia
- Arsenous_acid
- PDB Entries
- 1ihu / 1ii0 / 1ii9 / 1j9b / 1sjz / 1sk0 / 6dun
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA 1 3 Completed Treatment Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Promyelocytic Leukemia (M3) / Childhood Acute Promyelocytic Leukemia (M3) / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies 1 3 Completed Treatment Childhood Acute Promyelocytic Leukemia With PML-RARA / Myeloid Neoplasm 1 2 Completed Treatment Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer 1 2 Recruiting Treatment Acute Promyelocytic Leukemia With PML-RARA 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.86 Chemaxon pKa (Strongest Acidic) 6.84 Chemaxon pKa (Strongest Basic) -6.2 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 60.69 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 7.69 m3·mol-1 Chemaxon Polarizability 6.27 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7927 Blood Brain Barrier + 0.9045 Caco-2 permeable - 0.7089 P-glycoprotein substrate Non-substrate 0.8617 P-glycoprotein inhibitor I Non-inhibitor 0.9733 P-glycoprotein inhibitor II Non-inhibitor 0.9936 Renal organic cation transporter Non-inhibitor 0.9439 CYP450 2C9 substrate Non-substrate 0.8115 CYP450 2D6 substrate Non-substrate 0.8472 CYP450 3A4 substrate Non-substrate 0.7773 CYP450 1A2 substrate Non-inhibitor 0.9211 CYP450 2C9 inhibitor Non-inhibitor 0.9029 CYP450 2D6 inhibitor Non-inhibitor 0.9373 CYP450 2C19 inhibitor Non-inhibitor 0.9281 CYP450 3A4 inhibitor Non-inhibitor 0.9746 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9663 Ames test Non AMES toxic 0.8348 Carcinogenicity Carcinogens 0.6573 Biodegradation Not ready biodegradable 0.7344 Rat acute toxicity 1.7564 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8358 hERG inhibition (predictor II) Non-inhibitor 0.9621
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsArsenate reductase
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Unknown
- General Function
- Arsenate reductase (glutaredoxin) activity
- Specific Function
- Reduction of arsenate [As(V)] to arsenite [As(III)]. This protein expands the substrate specificity of ArsAB pump which can extrude arsenite and antimonite to allow for arsenate pumping and resista...
- Gene Name
- arsC
- Uniprot ID
- P08692
- Uniprot Name
- Arsenate reductase
- Molecular Weight
- 15830.1 Da
References
2. DetailsArsenical pump-driving ATPase
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Unknown
- General Function
- Atp binding
- Specific Function
- Anion-transporting ATPase. Catalyzes the extrusion of the oxyanions arsenite, antimonite and arsenate. Maintenance of a low intracellular concentration of oxyanion produces resistance to the toxic ...
- Gene Name
- arsA
- Uniprot ID
- P08690
- Uniprot Name
- Arsenical pump-driving ATPase
- Molecular Weight
- 63187.75 Da
References
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52